FIA
APYX icon

FNY Investment Advisers’s Apyx Medical APYX Stock Holding History

FNY Investment Advisers’s Portfolio APYX Stock Details APYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-8,319
Closed -$48K – 642
2022
Q2 		$48K Buy
+8,319
New +$42.7K 0.04% 234
2018
Q4 		– Sell
-5,000
Closed -$35K – 674
2018
Q3 		$35K Buy
+5,000
New +$27.8K 0.01% 401

Other funds holding APYX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
ACM
Archon Capital Management Seattle, Washington $246M AUM 130.69% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KLC
Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return
IP
Invenire Partners Ridgefield, Connecticut $65.4M AUM 18.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
HKAM
Horizon Kinetics Asset Management New York $8.82B AUM 23.05% 1-Year Est. Return

FNY Investment Advisers's APYX Position: Q3 2022 in Review

FNY Investment Advisers sold out of Apyx Medical (APYX) in Q3 2022, closing a stake of 8,319 shares — an estimated $48K sold.

FNY Investment Advisers first reported a position in APYX in Q3 2018 and held it in 2 quarters. The position peaked at $48K in Q2 2022. 54 funds tracked by Wall St. Rank hold APYX as of Q3 2022.

  • FNY Investment Advisers reported no remaining Apyx Medical position as of Q3 2022 after selling out during the quarter.
  • FNY Investment Advisers sold 8,319 Apyx Medical shares in Q3 2022, an estimated $48K.
  • FNY Investment Advisers first reported a position in Apyx Medical in Q3 2018 and held it in 2 quarters.
  • FNY Investment Advisers's Apyx Medical position peaked at $48K in Q2 2022.
  • 54 funds tracked by Wall St. Rank held Apyx Medical as of Q3 2022.

Based on FNY Investment Advisers's 13F filing for Q3 2022, filed 19 Oct 2022.